Replies to post #2272 on Skye Bioscience Inc (SKYE)

[AntonChigurh]

Doubt it. The latest placement by Schneider's it states that the conversion price would be adjusted for any r/s in the future. For the other 1m+ warrants and options, you would have to dig up the initial agreements. It is a good question. But again, knowing NMUS has such good people, I'm sure they would protect shareholders from that.

As far as a strategy, I posted the requirements for NASDAQ and NYSE listings yesterday. It is anyone's guess how much resources will be devoted to it, while they pursue their CINV and glaucoma indications.

[Vinpat]

I don't think they will attempt to uplist until the price is high enough to perhaps not even have to do a split. There's really no hurry now that they have cash. They'll be putting out news that will drive the price including clinical trial results and most likely a development deal. Keep in mind they will probably be able to qualify under the close price exceptions of either $2 or $3 per share and not have to be at $4.